FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Clinical trials for FALLOPIAN TUBE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing whether a combination of two oral drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemoth…
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists weaponize measles virus to fight ovarian cancer
Disease control OngoingThis study is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Doctors are using a specially engineered measles virus, which is carried directly to the cancer by the patient's own fat-derived stem cells, …
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Two-Pill attack on tough ovarian cancers
Disease control OngoingThis study is testing a combination of two oral drugs, olaparib and cediranib, to see if they can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is for women whose cancer has returned after previous treatment. The main goals are to see if the dru…
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC